• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Takeda renames Millennium as Takeda Oncology

Takeda renames Millennium as Takeda Oncology

December 10, 2014
CenterWatch Staff

Takeda Pharmaceutical has announced its global oncology business unit, headquartered in Cambridge, Mass., now will be called Takeda Oncology. The creation of Takeda Oncology will improve the company's ability to meet the unique and urgent needs of cancer patients, their loved ones and health care providers worldwide. Takeda will sustain its long-standing entrepreneurial approach to oncology R&D, while expanding its global commercial network and resources as Takeda Oncology.

Takeda is retiring the Millennium: The Takeda Oncology Company brand, replacing it with Takeda Oncology to reflect the new global oncology business unit.

Comprised of Takeda's global oncology commercial operations, the Oncology Business Unit remains closely aligned with Takeda's dedicated global oncology R&D function, the Oncology Therapeutic Area Unit and Takeda's Oncology Drug Discovery Unit to together drive forward the company's portfolio of products while maintaining a focus on expanding new product launches in the near and longer terms.

As a fully integrated unit within Takeda's global network, the Oncology Business Unit will leverage expertise from diverse oncology markets to help accelerate global and local capabilities, ensure continued understanding of evolving patient needs and drive the oncology business worldwide.

"Less than two years ago, Takeda reorganized R&D within oncology to provide an expanded, global reach while maintaining focus and dedicated resources to our therapeutic area. As a result, our R&D infrastructure across Takeda in oncology, which is focused on innovative products, is the strongest and most integrated it has ever been," said Michael Vasconcelles, M.D., head, Oncology Therapeutic Area Unit, Takeda.

Christopher Claiborne, Ph.D., head, Oncology Drug Discovery Unit, Takeda, said, "In working toward our aspiration to cure cancer, our singular focus has been on the discovery and development of breakthrough medicines for cancer patients, particularly for those battling forms of the disease that have not traditionally been the focus of oncology R&D. Now, with a more robust global network and resources, we are optimally positioned to leverage all scientific and clinical platforms and tools at our disposal to quickly identify new targets and develop compounds for cancer patients around the world."

Takeda's legacy in oncology extends more than 25 years, and includes a range of paradigm-changing therapies for hematologic cancers and solid tumors. Today, the company is investigating compounds across more than 17 forms of cancer, including ixazomib in AL amyloidosis and multiple myeloma as well as alisertib in relapsed/refractory peripheral T-cell lymphoma, recurrent ovarian cancer and small cell lung cancer, among other malignancies.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing